As your patients start a new therapy, reimbursement may be a concern. To help them get over this potential hurdle, Valeritas proudly provides expert, personalized insurance guidance and a variety of resources for your patients.
Medicare
V-Go® is covered by law as a Part D benefit.
According to CMS:
With the V-Go Cost Savings Card, commercially insured patients pay $0 for their first prescription at any retail pharmacy.† Refills cost $75 or less depending on their insurance benefit.
†30-day supply.
§30-day public notice of cancellation. This card is NOT valid for prescriptions that may be reimbursed under a federal or state healthcare program, including Medicare, Medicaid, or any other similar federal or state healthcare program, including any state pharmacy assistance program. This card is only valid for insured patients.
The terms of the previously available V-Go Co-pay Reduction Card, which was effective November 1, 2015 will no longer apply starting September 1, 2018.
Under the V-Go Co-pay Program, commercially-insured patients pay $0 for their first prescription and $75 or less, depending on insurance benefit. See details above.
If you have any questions, please contact V-Go Customer Care at 1-866-881-1209.
A real-world study, evaluating 86 patients switched from MDI to V-Go, showed significant (P=0.001) savings in direct pharmacy costs per patient per month.2,*†‡
Cost savings realized by the plan can be passed down to patients in the form of lower premiums and lower co-pays.
Reach out to V-Go Customer Care today at 1-866-881-1209 to speak to a V-Go Partner about any questions regarding the V-Go Cost Savings Card.
References: 1. Sutton D, Higdon C, Carmon M, Martinez J, Peasah S. Evaluating cost of therapy and clinical efficacy with V-Go in patients with sub-optimally controlled diabetes from an endocrine specialty system. Presented at the Academy of Managed Care Pharmacy Annual Meeting, San Francisco, CA. April 2016. [Poster] 2. Lajara R, Nikkel C. Evaluation of real-world clinical and pharmacy budget outcomes when switching to a wearable insulin delivery device for insulin administration in patients with sub-optimally controlled diabetes. Presented at: ISPOR 22nd Annual International Meeting, Boston MA. May 2017 [Poster]